---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316041"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2026-07-24T20:01:26+00:00"
generated_at: "2026-07-24T20:04:13.463597+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MannKind gets FDA approval for Furoscix ReadyFlow; raises $50M in private placement

## Summary
- FDA approved Furoscix ReadyFlow (furosemide injection) for edema in adults with heart failure or chronic kidney disease.
- Private placement of 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, led by Frazier Life Sciences.
- Gross proceeds ~$50M; net proceeds to fund $45M CVR payment triggered by FDA approval and for general corporate purposes.
- Pre-funded warrants have $0.01 exercise price, no expiration, subject to 19.99% beneficial ownership limitation.
- Company agreed to file resale registration statement within 30 days of closing.

## SEC filing metadata
- accession: 0001193125-26-316041
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2026-07-24T20:01:26+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/0001193125-26-316041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/d63182d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316041
- JSON: https://secwatch.observer/filing/0001193125-26-316041.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.